Employees Provident Fund Board’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$41M Buy
163,093
+17,959
+12% +$3.86M 0.24% 50
2026
Q1
$31.6M Buy
145,134
+134
+0.1% +$29.7K 0.24% 48
2025
Q4
$33.1M Hold
145,000
0.24% 50
2025
Q3
$33.6M Buy
145,000
+14,956
+12% +$3.05M 0.27% 50
2025
Q2
$24.1M Buy
130,044
+28,544
+28% +$5.3M 0.21% 59
2025
Q1
$21.3M Buy
101,500
+58,500
+136% +$11.4M 0.24% 59
2024
Q4
$7.64M Sell
43,000
-7,000
-14% -$1.29M 0.09% 75
2024
Q3
$9.87M Hold
50,000
0.14% 74
2024
Q2
$8.58M Buy
50,000
+2,000
+4% +$331K 0.14% 73
2024
Q1
$8.74M Sell
48,000
-2,400
-5% -$414K 0.15% 67
2023
Q4
$7.81M Buy
50,400
+1,400
+3% +$204K 0.15% 61
2023
Q3
$7.3M Buy
49,000
+50
+0.1% +$7.34K 0.17% 63
2023
Q2
$6.6M Buy
+48,950
New +$7.18M 0.16% 66
2021
Q1
Sell
-36,450
Closed -$3.91M 65
2020
Q4
$3.91M Hold
36,450
0.07% 67
2020
Q3
$3.19M Sell
36,450
-2,339
-6% -$220K 0.07% 61
2020
Q2
$3.81M Buy
+38,789
New +$3.42M 0.09% 59
2017
Q2
Sell
-98,673
Closed -$6.43M 51
2017
Q1
$6.43M Sell
98,673
-155,022
-61% -$9.75M 0.19% 51
2016
Q4
$15.9M Buy
253,695
+113,247
+81% +$6.91M 0.54% 37
2016
Q3
$8.86M Hold
140,448
0.32% 39
2016
Q2
$8.7M Sell
140,448
-163,094
-54% -$9.94M 0.37% 32
2016
Q1
$17.3M Sell
303,542
-202,070
-40% -$11.3M 0.74% 30
2015
Q4
$30M Sell
505,612
-721,488
-59% -$41.6M 1.02% 30
2015
Q3
$57.7M Buy
1,227,100
+610,467
+99% +$39.7M 2.19% 20
2015
Q2
$41.4M Sell
616,633
-132,967
-18% -$8.68M 1.45% 28
2015
Q1
$43.9M Sell
749,600
-59,244
-7% -$3.58M 1.49% 27
2014
Q4
$52.9M Buy
808,844
+261,295
+48% +$16.5M 1.62% 25
2014
Q3
$31.6M Sell
547,549
-77,503
-12% -$4.3M 1% 37
2014
Q2
$35.3M Buy
625,052
+125,052
+25% +$6.56M 1.11% 33
2014
Q1
$24.6M Hold
500,000
0.79% 36
2013
Q4
$26.4M Sell
500,000
-15,630
-3% -$768K 0.8% 36
2013
Q3
$23.1M Hold
515,630
0.83% 36
2013
Q2
$21.3M Buy
+515,630
New +$22.6M 0.86% 34

Other funds holding ABBV

Employees Provident Fund Board's ABBV Position: Q2 2026 in Review

Employees Provident Fund Board increased its AbbVie (ABBV) stake by 12% in Q2 2026, buying an estimated $3.86M and bringing the position to 163,093 shares worth $41M. The position accounts for 0.24% of the portfolio, ranked #50.

Employees Provident Fund Board first reported a position in ABBV in Q2 2013 and has held it in 32 quarters since. The position peaked at $57.7M in Q3 2015. 4,187 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Employees Provident Fund Board held 163,093 shares of AbbVie worth $41M as of Q2 2026.
  • Employees Provident Fund Board bought 17,959 AbbVie shares in Q2 2026, an estimated $3.86M.
  • AbbVie made up 0.24% of Employees Provident Fund Board's portfolio in Q2 2026, its #50 holding.
  • Employees Provident Fund Board first reported a position in AbbVie in Q2 2013 and has held it in 32 quarters since.
  • Employees Provident Fund Board's AbbVie position peaked at $57.7M in Q3 2015.
  • 4,187 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Employees Provident Fund Board's 13F filing for Q2 2026, filed 12 Aug 2026.